Pediatric cancers, though uncommon, are on the rise. As of 2014, there were almost
210,000 male survivors of childhood cancers that were diagnosed from ages 0 to 19 years in
the United States. With improved therapies and discovered cures, this number will continue
to rise as these patients continue to survive into adulthood (1). Unfortunately, many of these
therapies have gonadotoxic effects and challenge these men's ability to father children.
Therefore, it is imperative to address fertility preservation in this patient population before …